Lupin wins US FDA approval for vitamin K injection
In short
Lupin got US FDA approval for a prefilled vitamin K injection in the US. The reporting says the product is used for low blood clotting and vitamin K deficiency, and the US market is worth $52.3 million in annual sales.
This could add to Lupin’s US business, but the report does not say when the product will launch or how much sales it may bring.
What the reporting says
Lupin received US FDA approval for a prefilled vitamin K injection in the US, according to a publisher summary citing annual sales of $52.3 million. The product is used to treat low blood clotting and vitamin K deficiency. The reporting does not state when launches will begin or how much of the market Lupin expects to capture.
Why it matters
Lupin received US FDA approval for a prefilled vitamin K injection in the US, with the reporting citing $52.3 million in annual US sales for the market. The medicine is used for low blood clotting and vitamin K deficiency. This matters for Lupin’s US pharmaceutical portfolio and the injectable segment, but the reporting does not state launch timing, pricing, or expected revenue.